From the ∗U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino
†Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova
‡U.O. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino
§Division of Breast Surgery, Ospedale Villa Scassi e ASL3, Genova, Italy.
Conflicts of Interest and Source of Funding: F.P. received honoraria from Eli Lilly, Novartis, and Pfizer. M.L. had advisory role for Roche, Lilly, Novartis, Astrazeneca, MSD, Exact Sciences, Seagen, Gilead, and Pfizer and received speaker honoraria from Roche, Lilly, Novartis, Pfizer, Sandoz, Libbs, Knight, and Takeda outside the submitted work. M.L. acknowledges the Italian Association for Cancer Research (“Associazione Italiana per la Ricerca sul Cancro,” AIRC; MFAG 2020 ID 24698) and the Italian Ministry of Health (5 × 1000 funds 2017) for supporting his research in the field of breast cancer in young women and oncofertility. For the remaining authors, none were declared.
Reprints: Matteo Lambertini, MD, PhD, IRCCS Ospedale Policlinico San Martino, University of Genova, Largo Rosanna Benzi 10, 16132 Genova, Italy. E-mail: [email protected].
